Mathematical Modeling of Vaccines That Prevent SARS-CoV-2 Transmission.

ABSTRACT: SARS-CoV-2 vaccine clinical trials assess efficacy against disease (VE_DIS), the ability to block symptomatic COVID-19. They only partially discriminate whether VE_DIS is mediated by preventing infection completely, which is defined as detection of virus in the airways (VE_SUSC), or by preventing symptoms despite infection (VE_SYMP). Vaccine efficacy against transmissibility given infection (VE_INF), the decrease in secondary transmissions from infected vaccine recipients, is also not measured. Using mathematical modeling of data from King County Washington, we demonstrate that if the Moderna (mRNA-1273QS) and Pfizer-BioNTech (BNT162b2) vaccines, which demonstrated VE_DIS > 90% in clinical trials, mediate VE_DIS by VE

SUBMITTER: Swan DA 

PROVIDER: S-EPMC8539635 | biostudies-literature | 2021 Sep

REPOSITORIES: biostudies-literature